加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$1.08
US$0.00 · 0.00%
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
前收盘价
US$1.08
US$0.00 · 0.00%
盘中时间采用ET。市场数据可能有所延迟。
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
日内区间
当前US$1.08
52周区间
当前US$1.08
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
2
估值过高
情绪
51
多空交织
风险
47
风险偏高
动量
76
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
日内区间
当前US$1.08
52周区间
当前US$1.08
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.8万 USD | — | 65.1万 USD | — | 37.8万 USD |
| 销货成本 | — | 671.8万 USD | 554.6万 USD | 164.7万 USD | 300.6万 USD |
| 毛利 | 2.8万 USD | −671.8万 USD | −489.5万 USD | −164.7万 USD | −262.8万 USD |
| 研究与开发 | 603.3万 USD | 671.8万 USD | 554.6万 USD | 169.4万 USD | 243.5万 USD |
| 销售、一般及管理费用 | 747.9万 USD | — | — | 1701.1万 USD | — |
| 营业费用 | 1351.2万 USD | 853.4万 USD | 1199.4万 USD | 1870.5万 USD | 1548.8万 USD |
| 利息收入 | 43.6万 USD | 67.9万 USD | 673.6万 USD | 150.2万 USD | 316.2万 USD |
| 利息支出 | — | 39.4万 USD | 13.4万 USD | 111.6万 USD | 229.1万 USD |
| 折旧和摊销 | — | 9.6万 USD | 31.1万 USD | 164.7万 USD | 197.3万 USD |
| 营业利润 | −1348.4万 USD | −1525.2万 USD | −1688.9万 USD | −2035.2万 USD | −1811.6万 USD |
| 净利润 | −1429万 USD | −1300.4万 USD | −1839.7万 USD | 4251.5万 USD | −3509.9万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.00
上涨空间 177.78%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年10月26日 | 1:20 | — | — |
已生效 2022年10月26日
1:20
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
